Conner: Tell us about the new recommendations for the pneumonia vaccine.

This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers. Thomas Triomphe Executive Vice President, Vaccines, Sanofi ...

SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

SK bioscience and Sanofi, a global healthcare company, extended their partnership to co-develop next-generation pneumococcal ...

SK Bioscience and global pharmaceutical giant Sanofi signed an expanded agreement to jointly develop next-generation ...

SK Bioscience Co. Ltd. won €50 million (₩75.5 billion, US$52.03 million) up front from Sanofi SA to expand an earlier agreement to develop and commercialize novel pneumococcal conjugate vaccines (PCVs ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

根据高盛的说法，Vaxcyte的主打资产VAX-31的风险已经大大降低，这增强了对其监管进展和重大全球商业机会潜力的信心。高盛对Vaxcyte的展望包括扩大公司价值主张的潜力，预计管线资产的出现将创造持久长期增长的机会。

Prioritizing disease prevention naturally requires implementing effective immunization campaigns while also fostering an ...

Immunisation helps to strengthen your child's immune system to fight diseases like polio, measles, hepatitis B, diphtheria, ...

A total of 740 patients with COVID-19 also experienced myocarditis, compared to 55 patients who had flu and 65 with RSV. The ...